Crohn's disease treatment takes a step forward: New guidelines issued
The American Gastroenterological Society has issued new guidelines for treating Crohn's disease that is based on symptoms and treating inflammation. Past treatment was geared toward relieving symptoms that failed to prevent complications including fistulas, abscess and strictures, the group notes.
Physicians now have a new tool for treating Crohn's disease. Guidelines released by the American Gastroenterological Society (AGA) are geared toward treating inflammation rather than clinical symptoms.
Goal of Crohn's therapy is now deep remission
The new goal of therapy is "deep remission" of Crohn's disease, meaning physicians should make treatment decisions based on both symptoms and endoscopic remission.
Based on study reviews, gauging treatment based on patient symptoms fails to prevent complications that include abscesses, fistulas and strictures.
Inflammation is determined by tools that include endoscopy, the blood test C-reactive protein (CRP), MRI, CT scan and by taking tissue samples of the colon.
The AGA notes that treatment of Crohn's disease is "evolving". William J. Sandborn, MD, AGAF who authored of the clinical decision tool said in a press release: "This clinical support tool represents a big step forward for the treatment of Crohn's disease and was created using a rigorous review process."
- The new Crohn's disease treatment algorithm include budesonide, steroids and azathioprine for low-risk patients, and biologic therapy with tumor necrosis factor (TNF) antagonists, combined with budesonide, steroids and azathioprine for patients at high risk for complications.
- Drug monitoring is recommended for patients who lose response to biological therapy to help with decision making.
The new guidelines for Crohn's disease treatment is also designed to provide clinicians with a uniform approach for treating the inflammatory bowel disease.
Image credit: Wikimedia Commons